Your guide to peptide science
The clinical mind behind our peptide education program
Dr. Greene is one of a select few pharmacists in the country to hold A4M Peptide Therapy Certification. He leads Evergreen's internal peptide training program — ensuring every clinician on our team meets the highest clinical standards before a single protocol reaches a patient. His work centers on translating current peptide science into rigorous, prescriber-ready clinical education built for depth over surface-level summaries.
- PharmD
- FMCP — Functional Medicine Certified Practitioner
- IFM Certified Practitioner
- A4M Peptide Certified
"The difference between a well-formulated peptide protocol and a risky one isn't just the molecule. It's the compounding standards, the clinical oversight, and the education behind every decision."
Medically reviewed articles
A Note From Evergreen on the July 2026 PCAC Peptide Review
Our statement on the FDA Pharmacy Compounding Advisory Committee's July 23–24, 2026 review of seven peptides — six recommended, one rejected. None are legal to compound today.
DSIP (Emideltide) Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted against recommending DSIP (Emideltide) for the FDA Section 503A Bulks List. Compounding is not authorized — here's where things stand.
MOTS-c Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted to recommend MOTS-c for the FDA Section 503A Bulks List. Compounding is not yet legal — here's exactly where things stand.
Semax Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted to recommend Semax for the FDA Section 503A Bulks List. Compounding is not yet legal — here's exactly where things stand.
Epitalon Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted to recommend Epitalon for the FDA Section 503A Bulks List. Compounding is not yet legal — here's exactly where things stand.
TB-500 Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted to recommend TB-500 for the FDA Section 503A Bulks List. Compounding is not yet legal — here's exactly where things stand.
KPV Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted to recommend KPV for the FDA Section 503A Bulks List. Compounding is not yet legal — here's exactly where things stand.
BPC-157 Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted 8-6 to recommend BPC-157 for the FDA Section 503A Bulks List. Compounding is not yet legal — here's exactly where things stand.